Compare · HURA vs NVO
HURA vs NVO
Side-by-side comparison of TuHURA Biosciences Inc. (HURA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HURA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $187.53B, about 1389.0x HURA ($135.0M).
- Over the past year, HURA is down 23.8% and NVO is down 41.7% - HURA leads by 17.9 points.
- NVO has been more active in the news (11 items in the past 4 weeks vs 6 for HURA).
- NVO has more recent analyst coverage (25 ratings vs 4 for HURA).
- Company
- TuHURA Biosciences Inc.
- Novo Nordisk A/S
- Price
- $2.15-2.05%
- $42.01-2.10%
- Market cap
- $135.0M
- $187.53B
- 1M return
- -0.69%
- -5.38%
- 1Y return
- -23.80%
- -41.69%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- News (4w)
- 6
- 11
- Recent ratings
- 4
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest HURA
- TuHURA Biosciences Inc. filed SEC Form 8-K: Creation of a Direct Financial Obligation, Financial Statements and Exhibits
- Chief Executive Officer Bianco James A. gifted 150,000 shares, decreasing direct ownership by 6% to 2,173,307 units (SEC Form 4)
- SEC Form 10-Q filed by TuHURA Biosciences Inc.
- TuHURA Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Financial Statements and Exhibits
- TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update
- TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
- Amendment: SEC Form 8-K/A filed by TuHURA Biosciences Inc.
- Amendment: SEC Form 10-K/A filed by TuHURA Biosciences Inc.
- Citizens initiated coverage on TuHURA Biosciences with a new price target
- TuHURA Biosciences Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation, Unregistered Sales of Equity Securities, Regulation FD Disclosure
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care
- Peptide Wellness Market Could Near $300 Billion as Consumer Demand Accelerates